Xarelto

Xarelto is an anticoagulant medication primarily used to prevent and treat various types of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation. The drug is a product of a collaboration between Bayer AG, a German multinational pharmaceutical company, and Janssen Pharmaceuticals, Inc., a subsidiary of the American multinational corporation Johnson & Johnson. Bayer AG developed the active ingredient, rivaroxaban, and holds the marketing rights in certain regions. In the United States, Janssen Pharmaceuticals, Inc. markets and distributes Xarelto, making it the ultimate owner of the brand in this market. Manufacturing of Xarelto occurs in multiple countries, including facilities in Germany and the United States, to meet global demand. The collaboration between Bayer and Janssen combines Bayer's expertise in pharmaceutical development with Janssen's extensive distribution network, ensuring that Xarelto is accessible to patients worldwide.